Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
More News related to WMGI
- Wright Medical Group, Inc. to Host Fourth Quarter 2009 Earnings Conference Call
- Brigantine Advisors Initiates Coverage on Wright Medical Group (WMGI) with Hold; Comments on Valuation and Takeover Speculation
- Jefferies Starts ARTC, OFIX, ZMH, NUVA at Buy, WMGI, SYK at Hold
- Rodman & Renshaw Starts NXTM, THOR, MEND, SPNC at Outperform, EW, SRDX at Underperform
- Wright Medical Group, Inc. to Participate in 28th Annual J.P. Morgan Healthcare Conference
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
Wright Medical Group, Inc. (NASDAQ: WMGI) said the FDA has given approval to the Company to market its original CONSERVE® Plus Total Hip Resurfacing System. Now available in the United States, this innovative total surface arthroplasty system provides surgeons and their patients a bone-conserving alternative to traditional total hip replacement.
Related Categories
FDAStocks Mentioned
+0.41Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
